Skip to content
lifestyle.massnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Protagonist Therapeutics
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 18, 2026
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 18, 2026
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
February 24, 2026
←
Previous Page
1
2